https://www.live-feeds.com/feed/exclusive-gsk-sees-cancer-drug-pipeline-nearly-doubling-next-year-after-dealmaking-spreeContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/exclusive-gsk-sees-cancer-drug-pipeline-nearly-doubling-next-year-after-dealmaking-spreehttps://www.live-feeds.com/feed/exclusive-gsk-sees-cancer-drug-pipeline-nearly-doubling-next-year-after-dealmaking-spree#u163660Fri, 30 Oct 2026 11:15:15 +0000Pharmaceutical company GSK expects its clinical cancer-drug pipeline to nearly double next year following an aggressive dealmaking spree. The growth signals that the company's strategic return to oncology research is beginning to yield tangible portfolio expansion. Executives and industry analysts point to recent clinical data supporting antibody-drug conjugates, known as ADCs, as phase 3 pushes ramp up. This progress follows a focused corporate effort to rebuild the drugmaker's cancer research and development footprint through targeted acquisitions and partnerships.Why it mattersGSK